CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 46 enrolled
Drug / intervention
Infectious titre 1 (H3N2) +5 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02525055
NCT02525055N/ACompleted
CompareCT.gov

A Randomised, Double Blind Study To Characterise Influenza A/Perth/16/2009(H3N2) Virus

Hvivo·interventional·Posted Aug 17, 2015·Updated Jan 27, 2020

In Brief

A clinical study evaluating Infectious titre 1 (H3N2), Infectious titre 2 (H3N2), and 4 other interventions for Influenza. Completed, enrolled 46 participants.

Detailed Summary

The study will characterise Influenza A/Perth/16/2009(H3N2) virus in healthy participants using the viral challenge model. The study includes two cohorts. Cohort 1: A randomised, double-blind study of 4 titres of Challenge Virus to determine the optimum titre. Cohort 2: An open-label extension arm in which all participants will receive the 'optimum' titre as identified from Cohort 1.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 17, 2015
Enrollment StartJan 1, 2014
Primary CompletionAug 11, 2014
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.9 years ago

Interventions

Infectious titre 1 (H3N2)other

Infectious titre 1: 2.8 x 10\*3 TCID50/mL

Infectious titre 2 (H3N2)other

Infectious titre 2: 2.5 x 10\*4 TCID50/mL

Infectious titre 3 (H3N2)other

Infectious titre 3: 3.6 x 10\*5 TCID50/mL

Infectious titre 4 (H3N2)other

Infectious titre 4: 4.7 x 10\*6 TCID50/mL

Infectious titre 5 (H3N2) (Subjects aged 18 to 45 years old)other

Infectious titre 5: 3.5 x 10\*5 TCID50/mL

Infectious titre 5 (H3N2) (Subjects aged 46 to 64 years old)other

Infectious titre 5: 3.5 x 10\*5 TCID50/mL